pravastatin, Pravigard PAC (discontinued)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: pravastatin
BRAND NAME: Pravachol, Pravigard PAC (discontinued)
DRUG CLASS AND MECHANISM: Pravastatin is an oral drug for lowering the cholesterol in the blood that contributes to the formation of plaques in the walls of arteries that obstruct the flow of blood, known as arteriosclerotic vascular disease. Obstruction of the flow of blood to the heart causes heart attacks. Obstruction of flow to the brain causes strokes. Pravastatin has been shown to reduce the occurrence of heart attacks, strokes and death caused by arteriosclerotic vascular disease. It belongs to a class of drugs called HMG-CoA reductase inhibitors, commonly called "statins." Other statins include simvastatin (Zocor), lovastatin (Mevacor), atorvastatin (Lipitor), rosuvastatin (Crestor) and fluvastatin (Lescol). Statins reduce cholesterol by inhibiting an enzyme in the liver (HMG-CoA reductase) that is necessary for the production of cholesterol. In the blood, statins lower total and LDL ("bad") cholesterol as well as triglycerides. LDL cholesterol is believed to be an important cause of arteriosclerotic vascular disease. Lowering LDL cholesterol levels slows progression or reduces the size of cholesterol-containing plaques in the arteries of the heart and brain as well as other tissues. Statins also increase HDL ("good") cholesterol, and higher levels of HDL cholesterol are associated with reduced arteriosclerotic vascular disease. Raising HDL cholesterol levels may slow the progression of arteriosclerotic vascular disease.
Scientists have discovered that inflammation of the coronary arteries also may contribute to arteriosclerotic vascular disease. Inflammation is associated with elevated levels of a protein called C-reactive protein in the blood. This C-reactive protein can be measured by a test, referred to as the "highly-sensitive" C-reactive protein test (Hs-CRP). Elevated levels of Hs-CRP predict the occurrence of heart attacks, strokes, and death. In fact, Hs-CRP is a better predictor of heart attacks, strokes, and death than cholesterol levels. Statins reduce the levels of Hs-CRP, and it has been suggested that statins may reduce arteriosclerotic vascular disease by reducing inflammation in addition to lowering levels of cholesterol. Pravastatin was approved by the FDA in October 1991.
PRESCRIBED FOR: Pravastatin is used for treating individuals who have or are at risk for arteriosclerotic vascular disease and its consequences, heart attacks, and strokes. Pravastatin provides the following benefits:
SIDE EFFECTS: Like most statins, the most common side effects of pravastatin are:
The most serious potential side effects are liver damage and muscle inflammation or breakdown. Serious liver damage with statins is rare, however. More often, statins cause abnormalities of liver tests. Abnormal tests usually return to normal even if a statin is continued, but if the abnormal test is greater than three times the upper limit of normal, the statin usually is stopped. Liver tests should be measured before therapy is started and whenever there is a medical concern.
Inflammation of the muscles caused by statins can lead to a serious breakdown of muscle cells called rhabdomyolysis. When used alone, statins cause rhabdomyolysis in less than one percent of patients. Rhabdomyolysis causes the release of proteins from muscle (myoglobin) into the blood. Myoglobin can cause kidney failure and even death. To prevent the development of rhabdomyolysis, patients taking statins, including pravastatin, should contact their health care professional immediately if they develop unexplained muscle pain, weakness, or tenderness.
Since pravastatin prevents heart attacks, strokes and death, its benefit usually outweighs its serious but rare side effects. Other important side effects include post-marketing reports such as:
Symptoms may start one day to years after starting treatment and resolve within a median of three weeks after stopping the statin.
Medically Reviewed by a Doctor on 10/9/2015
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index